Compare · APLS vs XERS
APLS vs XERS
Side-by-side comparison of Apellis Pharmaceuticals Inc. (APLS) and Xeris Biopharma Holdings Inc. (XERS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APLS and XERS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- APLS is the larger of the two at $5.25B, about 4.5x XERS ($1.16B).
- Over the past year, APLS is up 112.9% and XERS is up 53.5% - APLS leads by 59.3 points.
- XERS has been more active in the news (12 items in the past 4 weeks vs 2 for APLS).
- APLS has more recent analyst coverage (25 ratings vs 12 for XERS).
- Company
- Apellis Pharmaceuticals Inc.
- Xeris Biopharma Holdings Inc.
- Price
- $41.05-0.05%
- $6.71+3.39%
- Market cap
- $5.25B
- $1.16B
- 1M return
- +0.48%
- +9.64%
- 1Y return
- +112.89%
- +53.55%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2018
- News (4w)
- 2
- 12
- Recent ratings
- 25
- 12
Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company also develops APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration, as well as is in Phase I/II clinical trial for acute respiratory distress syndrome. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Xeris Biopharma Holdings Inc.
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, small molecules, and proteins using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that has completed Phase II clinical trials for the treatment of post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, bi-hormonal artificial pancreas closed-loop systems, congenital hyperinsulinism, and hypoglycemia-associated autonomic failure; and hypoglycemia associated with intermittent and chronic conditions. In addition, it develops ready-to-use diazepam formulation, which is in Phase Ib clinical trial for the treatment of Dravet syndrome and acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is Phase II clinical trials for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is headquartered in Chicago, Illinois.
Latest APLS
- Amendment: SEC Form SCHEDULE 13G/A filed by Apellis Pharmaceuticals Inc.
- SEC Form 15-12G filed by Apellis Pharmaceuticals Inc.
- Director Dunlop A. Sinclair returned 20,311 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)
- VP/Chief Accounting Officer Chopas James George was granted 38,244 shares and returned 76,650 shares to the company, closing all direct ownership in the company (SEC Form 4) to satisfy withholding tax
- Director Dolsten Mikael returned 14,312 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding tax)
- Chief Research and Development Meltzer Leslie returned 174,854 shares to the company and was granted 67,830 shares, closing all direct ownership in the company (SEC Form 4) to cover withholding tax
- Director Fonteyne Paul R. returned 24,188 shares to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes
- Chief Financial Officer Sullivan Timothy Eugene was granted 159,080 shares and returned 270,413 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax liability)
- Director Machiels Alec returned 20,311 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding tax)
- Chief Scientific Officer Deschatelets Pascal was granted 90,040 shares and returned 135,445 shares to the company, closing all direct ownership in the company (SEC Form 4) to satisfy withholding obligation
Latest XERS
- Director Kong Garheng was granted 24,193 shares, increasing direct ownership by 11% to 238,337 units (SEC Form 4)
- Director Persky Marla sold $91,433 worth of shares (15,500 units at $5.90) as part of a pre-agreed trading plan and was granted 24,193 shares, increasing direct ownership by 6% to 150,693 units (SEC Form 4)
- Director Halkuff Dawn sold $121,886 worth of shares (20,000 units at $6.09) as part of a pre-agreed trading plan and was granted 24,193 shares, increasing direct ownership by 4% to 119,193 units (SEC Form 4)
- Director Bormann-Kennedy Barbara-Jean Anne sold $97,507 worth of shares (16,000 units at $6.09) as part of a pre-agreed trading plan and was granted 24,193 shares, increasing direct ownership by 6% to 150,693 units (SEC Form 4)
- Director Johnson John sold $91,422 worth of shares (15,000 units at $6.09) as part of a pre-agreed trading plan and was granted 24,193 shares, increasing direct ownership by 1% to 707,276 units (SEC Form 4)
- Director Brady James Aloysius was granted 24,193 shares, increasing direct ownership by 27% to 113,359 units (SEC Form 4)
- Xeris Biopharma Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 144 filed by Xeris Biopharma Holdings Inc.
- SEC Form 144 filed by Xeris Biopharma Holdings Inc.
- SEC Form 144 filed by Xeris Biopharma Holdings Inc.